{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-25-001357","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2025-09-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.573589+00:00","generated_at":"2026-05-17T05:38:47.096320+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Immunic presents positive vidofludimus calcium data at ECTRIMS, showing disability improvement in progressive MS","bullets":["Vidofludimus calcium achieved statistically significant 24-week confirmed disability improvement (HR 2.441, p=0.034) in Phase 2 CALLIPER trial in progressive multiple sclerosis.","Treatment reduced risk of 24-week confirmed disability worsening by 23.8% overall and 33.7% in patients without baseline Gd+ lesions.","Long-term EMPhASIS open-label extension data showed 92.7% of RRMS patients remained free of 24-week confirmed disability worsening at 144 weeks.","Preclinical EAE models demonstrated reduced T cell infiltration and increased neuroprotective markers with vidofludimus calcium.","Data from four poster presentations and one oral presentation highlighted Nurr1 activation as a novel neuroprotective mechanism."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-25-001357","json":"https://secwatch.observer/filing/0001193805-25-001357.json","markdown":"https://secwatch.observer/filing/0001193805-25-001357.md","text":"https://secwatch.observer/filing/0001193805-25-001357.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001357/0001193805-25-001357-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001357/e664856_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T05:38:47.096320+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}